Any prior echocardiographic measurement of LVEF
Acute coronary syndrome (including myocardial infarction [MI]),cardiac surgery, other major cardiovascular (CV) surgery, or urgent percutaneous coronary intervention (PCI) within the 3 months prior to Visit 1 or an elective PCI within 30 days prior to Visit 1.
Any clinical event within the 6 months prior to Visit 1 that could have reduced the LVEF (eg MI, coronary artery bypass graft [CABG]), unless an echo measurement was performed after the event confirming the LVEF to be ? 40% and LVEF? 45% by the time screening.
Current acute decompensated HF requiring augmented therapy with diuretics, vasodilators and/or inotropic drugs.
Current use of renin inhibitor(s).
History of hypersensitivity to LCZ696 or its components.
Patients with a known history of angioedema Walking distance primarily limited by non‐cardiac comorbid conditions.
-
Probable alternative diagnoses that in the opinion of the investigator could account for the patient’s HF symptoms (ie dyspnea, fatigue) such as significant pulmonary disease (including primary pulmonary HTN), anemia or obesity. Specifically, patients with the following are excluded:
a. severe pulmonary disease including chronic obstructive pulmonary disease (COPD) (ie requiring home oxygen, chronic nebulizer therapy, chronic oral steroid therapy or hospitalized for pulmonary decompensation within 12 months) or
b. hemoglobin (Hgb) or
c. body mass index (BMI) > 40 kg/m2
-
Patients with any of the following:
a. systolic blood pressure (SBP) ? 180 mmHg at Visit 1, or
b. SBP > 150 mmHg and patient is receiving 3 or more antihypertensive drugs. Antihypertensive drugs include, but are not limited to, a thiazide or other diuretic, MRA, ACEi, ARB, beta blocker and calcium channel blocker (CCB), or
c. SBP
Patients with HbA1c > 7.5% not treated for diabetes
Patients with history of any dilated cardiomyopathy, including peripartum cardiomyopathy, chemotherapy induced cardiomyopathy, or viral myocarditis.
Evidence of right sided HF in the absence of left‐sided structural heart disease
Known pericardial constriction, genetic hypertrophic cardiomyopathy, or infiltrative cardiomyopathy.
Clinically significant congenital heart disease that could be the cause of the patient’s symptoms and signs of HF.
Presence of hemodynamically significant valvular heart disease in the opinion of the investigator.
Stroke, transient ischemic attack, carotid surgery or carotid angioplasty within the 3 months prior to Visit 1.
Coronary or carotid artery disease or valvular heart disease likely to require surgical or percutaneous intervention during the trial.
Life‐threatening or uncontrolled arrhythmia, including symptomatic or sustained ventricular tachycardia and atrial fibrillation or flutter with a resting ventricular rate > 110 beats per minute (bpm).
Patients with a cardiac resynchronization therapy (CRT) device.
Patients with prior major organ transplant or intent to transplant(ie on transplant list)